Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs

L. E A Wildemberg; L. V. Neto; D. F. Costa; L. E. Nasciuti; C. M. Takiya; L. M. Alves; A. Rebora; F. Minuto; D. Ferone; M. R. Gadelha

doi:10.3275/8305

Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs

L. E A Wildemberg, L. V. Neto, D. F. Costa, L. E. Nasciuti, C. M. Takiya, L. M. Alves, A. Rebora, F. Minuto, D. Ferone, M. R. Gadelha

A.O.U. San Martino - IST, Istituto Nazionale Ricerca sul Cancro (GENOVA)

Research output: Contribution to journal › Article › peer-review

Abstract

Objectives: To evaluate somatostatin receptor 2A (SSTR2A) and dopamine receptor 2 (DR2) protein expression in somatotropinomas and to relate it to response to somatostatin analogues (SA). Design and patients: SSTR2A and DR2 expression was analyzed by immunohistochemistry in 88 somatotropinomas from patients submitted to either pre-surgical or adjuvant SA treatment. Tumors were scored according to percentage of immunostained cells: 0 (50%). Relation between protein expression and response to SA was performed in 66 patients. Response to SA was assessed by percent IGF-I reduction, being considered as an IGF-I per cent reduction higher than 50%. Disease control was also assessed (GH

Original language	English
Pages (from-to)	38-43
Number of pages	6
Journal	Journal of Endocrinological Investigation
Volume	36
Issue number	1
DOIs	https://doi.org/10.3275/8305
Publication status	Published - Jan 2013

Keywords

Acromegaly
Dopamine receptors
Immunohistochemistry
Somatostatin analogues
Somatostatin receptors

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.3275/8305

Cite this

Wildemberg, L. E. A., Neto, L. V., Costa, D. F., Nasciuti, L. E., Takiya, C. M., Alves, L. M., Rebora, A., Minuto, F., Ferone, D., & Gadelha, M. R. (2013). Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. Journal of Endocrinological Investigation, 36(1), 38-43. https://doi.org/10.3275/8305

Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. / Wildemberg, L. E A; Neto, L. V.; Costa, D. F.; Nasciuti, L. E.; Takiya, C. M.; Alves, L. M.; Rebora, A.; Minuto, F.; Ferone, D.; Gadelha, M. R.

In: Journal of Endocrinological Investigation, Vol. 36, No. 1, 01.2013, p. 38-43.

Research output: Contribution to journal › Article › peer-review

Wildemberg, LEA, Neto, LV, Costa, DF, Nasciuti, LE, Takiya, CM, Alves, LM, Rebora, A, Minuto, F, Ferone, D & Gadelha, MR 2013, 'Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs', Journal of Endocrinological Investigation, vol. 36, no. 1, pp. 38-43. https://doi.org/10.3275/8305

Wildemberg, L. E A ; Neto, L. V. ; Costa, D. F. ; Nasciuti, L. E. ; Takiya, C. M. ; Alves, L. M. ; Rebora, A. ; Minuto, F. ; Ferone, D. ; Gadelha, M. R. / Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. In: Journal of Endocrinological Investigation. 2013 ; Vol. 36, No. 1. pp. 38-43.

@article{70114c17b98b4c3e81e55191cb08db54,

title = "Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs",

abstract = "Objectives: To evaluate somatostatin receptor 2A (SSTR2A) and dopamine receptor 2 (DR2) protein expression in somatotropinomas and to relate it to response to somatostatin analogues (SA). Design and patients: SSTR2A and DR2 expression was analyzed by immunohistochemistry in 88 somatotropinomas from patients submitted to either pre-surgical or adjuvant SA treatment. Tumors were scored according to percentage of immunostained cells: 0 (50%). Relation between protein expression and response to SA was performed in 66 patients. Response to SA was assessed by percent IGF-I reduction, being considered as an IGF-I per cent reduction higher than 50%. Disease control was also assessed (GH",

keywords = "Acromegaly, Dopamine receptors, Immunohistochemistry, Somatostatin analogues, Somatostatin receptors",

author = "Wildemberg, {L. E A} and Neto, {L. V.} and Costa, {D. F.} and Nasciuti, {L. E.} and Takiya, {C. M.} and Alves, {L. M.} and A. Rebora and F. Minuto and D. Ferone and Gadelha, {M. R.}",

year = "2013",

month = jan,

doi = "10.3275/8305",

language = "English",

volume = "36",

pages = "38--43",

journal = "Journal of Endocrinological Investigation",

issn = "0391-4097",

publisher = "Springer International Publishing",

number = "1",

}

TY - JOUR

T1 - Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs

AU - Wildemberg, L. E A

AU - Neto, L. V.

AU - Costa, D. F.

AU - Nasciuti, L. E.

AU - Takiya, C. M.

AU - Alves, L. M.

AU - Rebora, A.

AU - Minuto, F.

AU - Ferone, D.

AU - Gadelha, M. R.

PY - 2013/1

Y1 - 2013/1

N2 - Objectives: To evaluate somatostatin receptor 2A (SSTR2A) and dopamine receptor 2 (DR2) protein expression in somatotropinomas and to relate it to response to somatostatin analogues (SA). Design and patients: SSTR2A and DR2 expression was analyzed by immunohistochemistry in 88 somatotropinomas from patients submitted to either pre-surgical or adjuvant SA treatment. Tumors were scored according to percentage of immunostained cells: 0 (50%). Relation between protein expression and response to SA was performed in 66 patients. Response to SA was assessed by percent IGF-I reduction, being considered as an IGF-I per cent reduction higher than 50%. Disease control was also assessed (GH

AB - Objectives: To evaluate somatostatin receptor 2A (SSTR2A) and dopamine receptor 2 (DR2) protein expression in somatotropinomas and to relate it to response to somatostatin analogues (SA). Design and patients: SSTR2A and DR2 expression was analyzed by immunohistochemistry in 88 somatotropinomas from patients submitted to either pre-surgical or adjuvant SA treatment. Tumors were scored according to percentage of immunostained cells: 0 (50%). Relation between protein expression and response to SA was performed in 66 patients. Response to SA was assessed by percent IGF-I reduction, being considered as an IGF-I per cent reduction higher than 50%. Disease control was also assessed (GH

KW - Acromegaly

KW - Dopamine receptors

KW - Immunohistochemistry

KW - Somatostatin analogues

KW - Somatostatin receptors

UR - http://www.scopus.com/inward/record.url?scp=84873603331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873603331&partnerID=8YFLogxK

U2 - 10.3275/8305

DO - 10.3275/8305

M3 - Article

C2 - 22472799

AN - SCOPUS:84873603331

VL - 36

SP - 38

EP - 43

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 1

ER -

Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this